Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinal Vein Occlusions Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

NCT01011374
View directory record Official record
Conditions
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions
ranibizumab (Lucentis)
Drug
Lead sponsor
Retina Associates of Cleveland, Inc
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

NCT03203447
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jul 21, 2026, 7:28 PM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated Phase 1 Interventional

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

NCT03790852
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 21, 2026, 7:28 PM EDT
Not listed Phase 1 Interventional

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120311
View directory record Official record
Conditions
Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Dexamethasone
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Jul 21, 2026, 7:28 PM EDT
Completed No phase listed Observational Results available

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

NCT01411696
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
dexamethasone intravitreal implant 0.7 mg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Jul 21, 2026, 7:28 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

NCT00211354
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT00500045
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
nicotinic acid
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated No phase listed Observational

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

NCT01875770
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 4 Interventional Results available

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
pegaptanib sodium injection
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Jul 21, 2026, 7:28 PM EDT
Completed No phase listed Observational

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

NCT02956330
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)

NCT01027650
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
AGN208397 intravitreal injection, dexamethasone intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Jul 21, 2026, 7:28 PM EDT
Recruiting Phase 2 Interventional

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

NCT07205887
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Interventions
EYE103, Aflibercept 2.0 mg
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
49
States / cities
Scottsdale, Arizona • Glendale, California • Modesto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 7:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Eye Institute Biorepository for Retinal Diseases

NCT01496625
View directory record Official record
Conditions
Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 120 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 7:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intravitreal Injection Site and Perceived Pain

NCT05640895
View directory record Official record
Conditions
Pain
Interventions
Intravitreal injection site
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

NCT04635800
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions
MHU650
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

NCT02245516
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Beverly Hills, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jul 21, 2026, 7:28 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT05127525
View directory record Official record
Conditions
Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions
IRX-101, Control
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Ozurdex for Retinal Vein Occlusion Study (ORVO Study)

NCT01790685
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
dexamethasone implant
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 3 Interventional Results available

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

NCT01969708
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
aflibercept, bevacizumab
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 21, 2026, 7:28 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02303184
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
4 mg CLS-TA, Sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Jul 21, 2026, 7:28 PM EDT